MoonLake Immunotherapeutics announced positive topline Week 16 results from its Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve patients with psoriatic arthritis, meeting all clinical endpoints. The primary endpoint of ACR50 response was achieved by 42.1% of patients treated with the 60 mg dose, while secondary endpoints showed 66.5% achieving ACR20, 41.2% Minimal Disease Activity, and 61% PASI90. The company reported second quarter 2026 financial results, ending with $537.0 million in cash and equivalents, sufficient to fund operations through mid-2028. MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing sonelokimab for inflammatory diseases.

On July 14, 2026, underwriters fully exercised their option to purchase an additional 1,500,000 Class A ordinary shares in the previously announced public offering. This exercise generated $30.0 million in additional gross proceeds for the company. MoonLake Immunotherapeutics is a biotechnology company focused on developing immunotherapies.

MoonLake Immunotherapeutics entered into an underwriting agreement with Leerink Partners LLC to issue and sell 9,000,000 Class A ordinary shares at $20.00 per share and up to 1,000,000 pre-funded warrants at $19.9999 per warrant. The gross proceeds from the offering is expected to offering $200 million. The offering is expected to close on June 25, 2026. MoonLake Immunotherapeutics is a biotechnology company focused on developing immunologicals for inflammatory diseases.

MoonLake Immunotherapeutics announced Week 52 results from its Phase 3 VELA-1 and VELA-2 clinical trials for sonelokimab (SLK) in adults with moderate-to-severe hidradenitis suppurativa (HS). Across both trials, 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100, with 26.0% achieving inflammatory remission (IHS4-100). The company reported that SLK responses were approximately 10% higher than a competing IL-17-A & F inhibitor. Additionally, interim Week 24 data from the Phase 3 VELA-TEEN trial in adolescents showed a 68% HiSCR75 response rate. The company operates in the biotechnology industry and develops therapies for inflammatory diseases.

MoonLake Immunotherapeutics held its 2026 Annual General Meeting of Shareholders on June 4, 2026, where shareholders approved an amendment and restatement of the 2022 Equity Incentive Plan to increase the number of available Class A Ordinary Shares for stock-based awards by 5,000,000 shares. The meeting also resulted in the election of Spike Loy as a Class I director nominee and the election of Baker Tilly US, LLP as independent auditor. MoonLake Immunotherapeutics is a biotechnology company focused on developing immunological and immunological-related therapies.